A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors.

Trial Profile

A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Planned end date changed from 1 Dec 2004 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top